Latest news
SK Biopharmaceuticals Establishes Dedicated IP Defense Unit for Xcopri, Bracing for Generic and New Drug Competition - finance.biggo.comfinance.biggo.com · Thu, 06 Aug 2026 07:06:00 GMTSK Biopharmaceuticals' Attributable Net Income Surges 158% in Q2; Shares Rise 5% - MoomooMoomoo · Wed, 05 Aug 2026 05:11:10 GMTSK Biopharmaceuticals Posts Record Q2 Operating Profit of ₩97.1 Billion on Surging US Xcopri Sales - finance.biggo.comfinance.biggo.com · Wed, 05 Aug 2026 02:27:00 GMTSK Biopharmaceuticals Posts Record Earnings on 45.6% Jump in Cenobamate U.S. Sales - Seoul Economic DailySeoul Economic Daily · Wed, 05 Aug 2026 01:37:51 GMTXcopri sales power SK Biopharmaceuticals to record Q2 profit - CHOSUNBIZ - ChosunbizChosunbiz · Wed, 05 Aug 2026 01:10:00 GMTSk Biopharmaceuticals Co Q2 Operating. Profit 97 Billion Won, Up 57% Y/Y - TradingViewTradingView · Wed, 05 Aug 2026 00:51:00 GMTSK Biopharmaceuticals expands Latin America push during Lee visit with epilepsy drug cenobamate - Korea JoongAng DailyKorea JoongAng Daily · Wed, 29 Jul 2026 05:43:21 GMTSK Biopharm expands Latin America push with Brazil launch - The Korea HeraldThe Korea Herald · Wed, 29 Jul 2026 05:19:48 GMT